Do we need different treatments for very elderly COPD patients?

Respiration

Volumn 80, Issue 5, 2010, Pages 357-368

  Valente, S ^a   Pasciuto, G ^a   Bernabei, R ^a   Corbo, G M ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Adverse drug events; Ageing; Chronic obstructive pulmonary disease; Compliance; Pharmacodynamics; Pharmacokinetics; Polypharmacy; Prescriptions, appropriate; Respiratory system

Indexed keywords

17 BECLOMETASONE MONOPROPIONATE; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CARBON 14; CHLORDIAZEPOXIDE; CHLORDIAZEPOXIDE PLUS CLIDINIUM BROMIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLORAZEPATE; CORTICOSTEROID; DIAZEPAM; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE; FORMOTEROL; HALAZEPAM; IPRATROPIUM BROMIDE; LIMBITROL; PROPRANOLOL; QUAZEPAM; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE; UNCLASSIFIED DRUG;

ACIDOSIS; ADRENAL SUPPRESSION; ADVERSE OUTCOME; AGING; ASTHMA; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONSTIPATION; CONVULSION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PENETRATION; DRUG TISSUE LEVEL; DRUG TOLERABILITY; FOOD DRUG INTERACTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART ARRHYTHMIA; HEART FAILURE; HEART PALPITATION; HERB DRUG INTERACTION; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; INSOMNIA; ISCHEMIC HEART DISEASE; ISOTOPE LABELING; LUNG FUNCTION TEST; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NONHUMAN; OSTEOPOROSIS; PFAPA SYNDROME; PHYSICAL CHEMISTRY; PNEUMONIA; POLYPHARMACY; POTASSIUM BLOOD LEVEL; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN BRUISING; TACHYCARDIA; TREMOR; URINARY TRACT INFECTION; VOMITING; XEROSTOMIA;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; AGING; ALBUTEROL; BRONCHODILATOR AGENTS; GLUCOCORTICOIDS; HUMANS; MEDICATION ADHERENCE; POLYPHARMACY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY MUSCLES; RESPIRATORY PHYSIOLOGICAL PHENOMENA; SCOPOLAMINE DERIVATIVES;

EID: 77958073839     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320221     Document Type: Review

References (108)

1. The United Nations: World Population Prospects: The 2008 Revision. 2010. http://www. un.org/esa/population/.
2. Turnheim K: Drug dosage in the elderly: is it rational? Drugs Aging 1998; 13: 357-379.
3. Aalami OO, Fang TD, Song MH, Nacamuli RP: Physiological features of aging persons. Arch Surg 2003; 138: 1068-1076.
4. Global Initiative for Chronic Obstructive Lung Disease. http://www.goldcopd.org. Updated 2009.
5. Enright PL, Kronnel RA, Manolio TA, et al: Respiratory muscle strength in the elderly: correlates and reference values. Am J Crit Care Med 1996; 149: 430-438.
6. Sharma G, Goodwin J: Effect of aging on respiratory system physiology and immunology. Clin Inter v Aging 2006; 1: 253-260.
7. Buchman AS, Boyle PA, Wilson RS, et al: Pulmonary function, muscle strength and mortality in old age. Mech Ageing Dev 2008; 129: 625-631.
8. Mannino DM: COPD: Epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002; 121(suppl5):121S-126S.
9. Craig BM, Kraus CK, Chewning BA, Davis JE: Quality of care for older adults with chronic obstructive pulmonary disease and asthma based on comparisons to practice guidelines and smoking status. BMC Health Serv Res 2008; 8:144-152.
10. Connolly MJ, Lowe D, Anstey K, et al: Admissions to hospital with exacerbations of chronic obstructive pulmonary disease: effect of age-related factors and service organization. Thorax 2006; 61:843-848.
11. Hilmer SN, McLachlan AJ, Le Couteur DG: Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol 2007; 21:217-230
12. Feldman M: The mature stomach: still pumping out acid? JAMA 1997; 278: 681-682.
13. Wiley JM: Aging and neural control of the GI tract. III. Senescent enteric nervous system: lessons from extraintestinal sites and non-mammalian species. Am J Physiol Gastroin-test Liver Physiol 2002; 283: G1020-G1026.
14. Orr WC, Chen CL: Aging and neural control of the GI tract. I V. Clinical and physiological aspects of gastrointestinal motility and aging. Am J Physiol Gastrointest Liver Physiol 2002; 283:G1226-G1231.
15. Bhutto A, Morley JE: The clinical significance of gastrointestinal changes with aging. Curr Opin Clin Nutr Metab Care 2008; 11: 651-660.
16. Saltzman JR, Kowdley K V, Perrone G, Russell RM: Changes in small-intestine permeability with aging. J Am Geriatr Soc 1995; 43: 160-164.
17. Kinirons MT, Crome P: Clinical pharmaco-kinetic considerations in the elderly: an update. Clin Pharmacokinet 1997; 33:302-312.
18. Morley JE: The aging gut: physiology. Clin Geriatr Med 2007; 23: 757-767.
19. Vi ncken W, Dek huijzen R , Barnes P, ADMIT Group: The ADMIT series-issues in inhalation therapy. IV. How to choose inhaler devices for the treatment of COPD. Prim Care Respir J 2010; 19: 10-20 .
20. Jarvis S, Ind PW, Shiner RJ: Inhaled therapy in elderly COPD patients: time for re-evaluation? Age Ageing 2007; 36:213-218.
21. Forbes GB, Reina JC: Adult lean body mass declines with age: some longitudinal observations. Metabolism 1970; 19: 653-663.
22. Beaufrere B, Morio B: Fat and protein redistribution with aging: metabolic considerations. Eur J Clin Nutr 2000; 54:S48-S53.
23. Campion EW, de Labry LO, Glynn RJ: The effect of age on serum albumin in healthy males: report from the Normative Aging Study. J Gerontol 1988; 43:M18-M20.
24. Verbeeck RK, Cardinal JA, Wallace SM: Effect of age and sex on the plasma binding of acidic and basic drugs. Eur J Clin Pharmacol 1984; 27:91-97.
25. Benet LZ, Hoener BA: Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 71: 115-121.
26. McLean AJ, Le Couteur DG: Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004; 56: 163-184.
27. Le Couteur DG, McLean AJ: The aging liver: drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998; 34: 359-373.
28. Turnheim K: When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003; 38:843-853.
29. Schmucker DL: Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging. 2001; 18 : 837-851.
30. Beck LH: Changes in renal function with aging. Clin Geriatr Med 1998; 14: 199-209.
31. Lindeman RD, Tobin J, Shock NW: Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278-285.
32. Fliser D, Franek E, Joest M, et al: Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int 1997; 51: 1196-1204.
33. Lindeman RD: Changes in renal function with aging: implications for treatment. Drugs Aging 1992; 2: 423-431.
34. Muhlberg W, Platt D: Age-dependent changes of the kidneys: pharmacological implications. Gerontology 1999; 45:243-253.
35. Spiriva HandiHaler package insert. Ridge-field, Boehringer Ingelheim Pharmaceuticals, 2004.
36. Van Noord JA, Cornelissen PJ, Aumann JL, et al: The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med 2009; 103:22-29.
37. Barnes PJ: The pharmacological properties of tiotropium. Chest 2000; 117:63S-66S.
38. Cazzola M, Testi R, Matera GM: Clinical pharmacokinetics of salmeterol. Clin Phar-macokinet 2002; 41:19-30.
39. Symbicort® Turbuhaler® summary of product characteristics. AstraZeneca UK Limited, 2005.
40. Daley-Yates PT, Tournant J, Kunka RL: Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma. Clin Pharmacoki-net 2000; 39(suppl 1):39-45.
41. Singh SD, Whale C, Houghton N, et al: Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease. Br J Clin Pharmacol 2003; 55: 375-381.
42. Mackie AE, Falcoz C, McDowall JE, et al: Pharmacokinetics of fluticasone propionate inhaled from the Diskhaler and the Diskus powder devices in healthy subjects. Br J Clin Pharmacol 1997; 43: 540P.
43. Hempfling W, Grunhage F, Dilger K, et al: Pharmacokinetics and pharmacodynamic action of budesonide in eary-and late-stage primary biliary cirrhosis. Hepatology 2003; 38: 196-202.
44. Mortimer KJ, Tattersfield AE, Tang Y, et al: Plasma concentration of fluticasone propio-nate and budesonide following inhalation: effect of induced bronchoconstriction. Br J Clin Pharmacol 2007; 64: 439-444.
45. Harrison TW, Tattersfield AE: Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax 2003; 58: 258-260.
46. Bowie MW, Slattum PW: Pharmacodynam-ics in older adults: a review. Am J Geriat Pharmacother 2007; 5:263-303.
47. Shi S, Klotz U, Morike K: The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol 2008; 64: 183-199.
48. HasaniA, Toms N, Agnew JE: The effect of inhaled tiotropoum bromide on lung muco-ciliary clearance in patients with COPD. Chest 2004; 125:1726-1734.
49. Willis-Karp M: Age-related changes in pulmonary muscarinic receptor binding proper ties. Am J Physiol 1993; 265:L103-L109.
50. Lee HK, Lim MY, Bok SM, et al: Age differences in cholinergic airway responsiveness in relation with muscarinic receptor subtypes. Life Sci 2007; 81: 204-209.
51. Op't Holt TB: Inhaled beta agonists, Respir Care, 2007, 52, 820-832.
52. Scarpace PJ: Decreased receptor activation with age: can it be explained by desensitiza-tion? J Am Geriatr Soc 1988; 36:1067-1071.
53. Turnheim K: Drug dosage in the elderly: is it rational? Drugs Aging 1998; 13: 357-379.
54. Connolly MJ, Crowley JJ, Charan NB, Niel-son CP, Vestal RE: Impaired bronchodilator response to albuterol in healthy elderly men and women. Chest 1995; 108:401-406.
55. Ullah MI, Newman GB, Saunders KB: Influence of age on response to ipratropium and salbutamol in asthma. Thorax 1981; 36:523-529.
56. Johannsson SA, Anderson FE, Brattsand R, Gruvstad E, Hedner P: Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man. Eur J Clin Pharmacol 1982; 22:523-529. (Pubitemid 12059197)
57. Phillips GH: Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med 1990; 84(suppl A):19-23.
58. Andersson N, Klint S, Randwall G, Wiren JE: Equipotency of budesonide and fluticasone propionate in the vasoconstriction assay. Am J Respir Crit Care Med 1994; 149:A467.
59. Dahlberg E, Thalen A, Brattsand R, et al: Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16alpha, 17al-phaacetal-substituted glucocorticoids. Mol Pharmacol 1984; 25:70-78.
60. Schwartz JB: The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 2007; 82: 87-96.
61. Fialova D, Topinkova E, Gambassi G, Ad-HOC Project Research Group: Potentially inappropriate medication use among elderly home care patients in Europe. JAMA 2005; 293:1348-1358.
62. Cole A: Over 60s' use of prescription drugs has doubled in past decade in England. BMJ 2008; 337:1132-1136.
63. Roth MT, Ivey JL: Self-reported medication use in community-residing older adults: a pilot study. Am J Geriatr Pharmacother 2005; 3: 196-20 4.
64. Pizzuti R, Caffari B, Binkin N, Gruppo AR-GENTO: Prescription drugs and the elderly: results of the Argento study (in Italian). Ig Sanita Publica 2006; 62: 11-26.
65. Kennerfalk A, Ruigomez A, Wallander MA, Wilhelmsen L, Johansson S: Geriatric drug therapy and healthcare utilization in the United Kingdom. Ann Pharmacother 2002; 36: 797-803.
66. Fradà G, Bennati E, Cardillo E, Ferlito L, Motta M, IMUSCE: Pharmacotherapy in the extreme longevity. Arch Gerontol Geriatr 2009; 49:60-63.
67. Steinman MA, Landefeld CS, Rosenthal GE, et al: Polypharmacy and prescribing quality in older people. J Am Geriatr Soc 2006; 54: 1516-1523.
68. Van der Hooft CS,'t Jong GW, Dieleman JP, et al: Inappropriate drug prescribing in older adults: the updated 2002Beers criteria-a population-based cohort study, Br J Clin Pharmacol, 2005, 60, 137-144.
69. Onder G, Landi F, Cesari M, Gambassi G, Carbonin P, Bernabei R, Investigators of the GIFA study: Inappropriate medication use among hospitalized older adults in Italy: results from the Italian Group of Pharmaco-epidemiology in the Elderly. Eur J Clin Pharmacol 2003; 59: 157-162.
70. Sorensen L, Stokes JA, Purdie DM, et al: Medication management at home: medication-related risk factors associated with poor healt h outcomes. Age Ageing 2005; 34: 626-632.
71. Ryan C, O'Mahony D, Kennedy J, Weedle P, Byrne S: Potentially inappropriate prescribing in an Irish elderly population in primary care. Br J Clin Pharmacol 2009; 68: 936-947.
72. Beers MH, Ouslander JG, Rollingher I, et al: Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med 1991; 151: 18 25-18 32.
73. Fick DM, Cooper JW, Wade WE, et al: Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163:2716-2724.
74. Naugler CT, Brymer C, Stolee P, et al: Development and validation of an improving prescribing in the elderly tool. Can J Clin Pharmacol 2000; 7:103-107.
75. Hanlon JT, Scmader KE, Samsa GP, et al: A method for assessing drug therapy appropriateness. J Clin Epidemiol 1992; 45:1045-1051.
76. Gallagher P, Ryan C, Byrne S, et al: STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment): consensus validation. Int J Pharmacol Ther 2008; 46:72-83.
77. Barry PJ, O'Keefe N, et al: Inappropriate prescribing in the elderly: a comparison of the Beers criteria and the improved prescribing in the elderly tool (IPET) in acutely ill elderly hospitalized patients. J Clin Pharm Ther 2006; 31: 617-626.
78. Gallagher P, O'Mahony D: STOPP (Screening Tool of Older Person's potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers criteria. Age Ageing 2008; 37: 673-679.
79. Vestal RE: Aging and pharmacology. Cancer 1997; 80: 1302-1310.
80. Council of Europe. Committee of experts on management of safety and quality in health care (SP-SQS): expert group on safe medication practices. Glossary of terms related to patient and medication safety. 2005. http:// www.bvs.org.ar.
81. Mallet L, Spinewine A, Huang A: The challenge of managing drug interactions in elderly people. La ncet 2007; 370: 185-191.
82. Walker J, Wynne H: The frequency and severity of adverse drug reactions in elderly people. Age Ageing 1994; 23: 255-259.
83. Björkman IK, Fastbom J, Schmidt IK, Bern-sten CB, Pharmaceutical Care of the Elderly in Europe Research (PEER) Group: Drug-drug interactions in the elderly. Ann Phar-macother 2002; 36:1675-1681.
84. Cohen JS: Avoiding adverse reactions: effective lower-dose drug therapies for older patients. Geriatrics 2000; 55: 54-56, 59-60, 63-64.
85. Col N, Fanale JE, Kronholm P: The role of medication non-compliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med 1990; 150:841-845.
86. Mjorndal T, Boman MD, Hagg S, et al: Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol Drug Saf 2002; 11: 65-72.
87. Mannesse CK, Derkx FH, De Ridder MA, et al: Contribution of adverse drug reactions to hospital admission in older patients. Age Ageing 2000; 29: 35-39.
88. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-1205.
89. Ziere G, Dieleman JP, Hofman A, et al: Poly-pharmacy and falls in the middle age and elderly population. Br J Clin Pharmacol 2006; 61:218-223.
90. Onder G, Pedone C, Landi F, Cesari M, Del-la Vedova C, Bernabei R, Gambassi G: Adverse drug reactions as a cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc 2002; 50: 1962-1968.
91. Bero LA, Lipton HL, Bird JA: Characterization of geriatric drug-related hospital read-missions. Med Care 1991; 29:989-1003.
92. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB: Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008; 63: 301-305.
93. Van Gestel YR, Hoeks SE, Sin DD, Welten GM, Schouten O, Witteveen HJ, Simsek C, Stam H, Mertens FW, Bax JJ, et al: The impact of cardioselective fS-blockers on mortality in patients with COPD and atherosclerosis. Am J Resp Crit Care Med 2008; 178: 695-700.
94. Lee TA, Pickard AS, Au DH, et al: Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008; 149: 380-390.
95. Singh S, Loke YK, Furberg CD: Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300: 1439-1450.
96. Faul JL, Tormey W, Burke C: High dose inhaled corticosteroids and dose dependant loss of diabetic control. BMJ 1999; 317:1491.
97. Cumming RG, Mitchel P, Leeder S: Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337:8-14. (Pubitemid 27290841)
98. Tashkin DP, Murray HE, Skeans M, Murray RP: Skin manifestations of inhaled cortico-steroids in COPD patients: results from Lung Health Study II. Chest 2004; 126: 1123-1133.
99. Weiner P, Berar-Yanay N, Davidovich A, Magadle R: Nocturnal cortisol secretion in asthmatic patients after inhalation of fluti-casone propionate. Chest 1999; 116: 931-934.
100. Wong CA, Walsh LJ, Smith CJP, et al: Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 2000; 355: 1399-1403.
101. Calverley PM, Anderson JA, Cell B, et al, TORCH investigators: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-798.
102. Ernst P, Gonzalez AV, Brassard P, Suissa S: Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176:162-166.
103. Au WY, Dutt AK, DeSoyza N: Theophylline kinetics in chronic obstructive airway disease in the elderly. Clin Pharmacol Ther 1985; 37: 472-478.
104. Chen CY, Yang KY, Lee YC, Perng PP: Effect of oral aminophylline on pulmonary function improvements and tolerability in different age groups of COPD patients. Chest 2005; 128:2088-2092.
105. Armijo JA, Sanchez BM, Peralta FG, et al: Pharmacokinetics of an ultralong sustained-release theophylline formulation given twice daily in elderly patients with chronic obstructive pulmonary disease: monitoring implications. Biopharm Drug Dispos 2003; 24: 165-171.
106. Vinks TH, de Koning FH, de Lange TM, Egberts TC: Identification of potential drug-related problems in the elderly: the role of the community pharmacist. Pharm World Sci 2006; 28:33-38.
107. Hanlon JT, Lindblad CI, Gray SL: Can clinical pharmacy services have a positive impact on drug-related problems and health outcomes in community-based older adults? Am J Geriatr Pharmacother 2004; 2: 3-13.
108. Crome P: What's different about older people. Toxicology 2003; 192: 49-54.